Intra-Cellular Stock Today


USD 55.17  1.91  3.35%   

Market Performance
0 of 100
Odds Of Distress
Over 52
Intra-Cellular Ther is trading at 55.17 as of the 4th of July 2022. This is a -3.35% down since the beginning of the trading day. The stock's open price was 57.08. Intra-Cellular Ther has 52 percent odds of going through some form of financial distress in the next two years and has generated negative returns to investors over the last 90 days. Equity ratings for Intra-Cellular Ther are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 14th of July 2020 and ending today, the 4th of July 2022. Click here to learn more.
Fiscal Year End
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
7th of January 2014
Health Care
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. The company has 81.46 M outstanding shares of which 3.34 M shares are currently shorted by private and institutional investors with about 3.65 trading days to cover. More on Intra-Cellular Ther

Intra-Cellular Ther Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. If you consider yourself one of those investors, make sure you clearly understand your entering position. Intra-Cellular Ther's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Intra-Cellular Ther or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Intra-Cellular Ther generated a negative expected return over the last 90 days
Intra-Cellular Ther has high historical volatility and very poor performance
Intra-Cellular Ther has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 83.8 M. Net Loss for the year was (284.13 M) with loss before overhead, payroll, taxes, and interest of (13.08 M).
Intra-Cellular Ther currently holds about 412.33 M in cash with (259.54 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.41.
Intra-Cellular Ther has a frail financial position based on the latest SEC disclosures
Over 87.0% of the company shares are owned by institutional investors
Latest headline from Revealed 10 shares the worlds top investors are buying in the selloff - Citywire USA
ChairmanSharon Mates
Fama & French Classification
Average Analyst Recommendation
Analysts covering Intra-Cellular Ther report their recommendations after researching Intra-Cellular Ther's financial statements, talking to executives and customers, or listening in on Intra-Cellular Ther's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Intra-Cellular Ther. The Intra-Cellular consensus assessment is calculated by taking the average forecast from all of the analysts covering Intra-Cellular Ther.
Piotroski F Score
Piotroski F-Score is a popular financial indicator that puts together nine criteria to evaluate the financial strength of Intra-Cellular Ther based on its profitability, leverage, liquidity, source of funds, and operating efficiency. It is an academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Intra-Cellular Ther financial position. Scores of 8 and 9 are usually classified as strong value stocks, whereas scores of 2 or below are considered weak value stocks.
 3 - FrailDetails
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares66.4 M81.3 M
Significantly Down
Slightly volatile
Weighted Average Shares Diluted66.5 M81.3 M
Significantly Down
Slightly volatile
Net Cash Flow from Operations(266.4 M)(259.5 M)
Fairly Down
Slightly volatile
Total Assets435.4 M489.9 M
Fairly Down
Slightly volatile
Total Liabilities77.7 M72 M
Significantly Up
Slightly volatile
Current Assets419.5 M467.3 M
Moderately Down
Slightly volatile
Current Liabilities57.6 M53.4 M
Significantly Up
Slightly volatile
Total Debt28.4 M25.4 M
Moderately Up
Slightly volatile
Gross Margin0.890.904
Fairly Down
Slightly volatile
Asset Turnover0.150.143
Sufficiently Up
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Intra-Cellular Ther's available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Financial Strength
Intra-Cellular Ther's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Intra-Cellular Ther's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Intra-Cellular Ther's financial leverage. It provides some insight into what part of Intra-Cellular Ther's total assets is financed by creditors.
Share Download
Share Download
By using current balance sheet information, investors can analyze the liability, assets, and equity on Intra-Cellular Ther's books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Intra-Cellular Ther deploys its capital and how much of that capital is borrowed.
Intra-Cellular Ther cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 25.41 M in liabilities with Debt to Equity (D/E) ratio of 0.06, which may suggest the company is not taking enough advantage from borrowing. Intra-Cellular Ther has a current ratio of 8.58, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Intra-Cellular Ther until it has trouble settling it off, either with new capital or with free cash flow. So, Intra-Cellular Ther's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Intra-Cellular Ther sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Intra-Cellular to invest in growth at high rates of return. When we think about Intra-Cellular Ther's use of debt, we should always consider it together with cash and equity.

Operating Cash Flow

(266.37 Million)Share
Intra-Cellular Ther (ITCI) is traded on NASDAQ Exchange in USA. It is located in 430 East 29th Street, New York, NY 10016, United States and employs 512 people. Intra-Cellular Ther is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with current market capitalization of 4.49 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Intra-Cellular Ther's market, we take the total number of its shares issued and multiply it by Intra-Cellular Ther's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Intra-Cellular Ther conducts business under Healthcare sector and is part of Drug Manufacturers—Specialty & Generic industry. The entity has 81.46 M outstanding shares of which 3.34 M shares are currently shorted by private and institutional investors with about 3.65 trading days to cover. Intra-Cellular Ther currently holds about 412.33 M in cash with (259.54 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.41.
Check Intra-Cellular Ther Probability Of Bankruptcy
Intra-Cellular Ther has a total of eighty-one million four hundred sixty thousand outstanding shares. The majority of Intra-Cellular Ther outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Intra-Cellular Ther to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Intra-Cellular Ther. Please pay attention to any change in the institutional holdings of Intra-Cellular Ther as this could imply that something significant has changed or about to change at the company. Please note that no matter how much assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.

Ownership Allocation (%)

Check Intra-Cellular Ownership Details

Intra-Cellular Stock Price Odds Analysis

What are Intra-Cellular Ther's target price odds to finish over the current price? In reference to a normal probability distribution, the odds of Intra-Cellular Ther jumping above the current price in 90 days from now is about 64.62%. The Intra-Cellular Ther probability density function shows the probability of Intra-Cellular Ther stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days Intra-Cellular Ther has a beta of 0.9237. This usually indicates Intra-Cellular Ther market returns are reactive to returns on the market. As the market goes up or down, Intra-Cellular Ther is expected to follow. Additionally, the company has an alpha of 0.0752, implying that it can generate a 0.0752 percent excess return over DOW after adjusting for the inherited market risk (beta).
  Odds Below 55.17HorizonTargetOdds Above 55.17
35.23%90 days
Based on a normal probability distribution, the odds of Intra-Cellular Ther to move above the current price in 90 days from now is about 64.62 (This Intra-Cellular Ther probability density function shows the probability of Intra-Cellular Stock to fall within a particular range of prices over 90 days) .

Intra-Cellular Stock Institutional Holders

Institutional Holdings refers to the ownership stake in Intra-Cellular Ther that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Intra-Cellular Ther's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Intra-Cellular Ther's value.
InstituionSecurity TypeTotal SharesValue
Fmr LlcCommon Shares11 M670.3 M
Vanguard Group IncCommon Shares7.8 M476.6 M
View Intra-Cellular Ther Diagnostics

Intra-Cellular Ther Historical Income Statement

Intra-Cellular Ther Income Statement is one of the three primary financial statements used for reporting Intra-Cellular's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Intra-Cellular Ther revenue and expense. Intra-Cellular Ther Income Statement primarily focuses on the company's revenues and expenses during a particular period.
Intra-Cellular Ther Operating Expenses is most likely to increase significantly in the upcoming years. The last year's value of Operating Expenses was reported at 361.46 Million. The current Revenues is estimated to increase to about 90.4 M, while Consolidated Income is projected to decrease to (291.6 M). View More Fundamentals

Intra-Cellular Stock Against Markets

Picking the right benchmark for Intra-Cellular Ther stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Intra-Cellular Ther stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Intra-Cellular Ther is critical whether you are bullish or bearish towards Intra-Cellular Ther at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Intra-Cellular Ther without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Headlines Timeline Now


Headlines Timeline

Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
All  Next Launch Module

Intra-Cellular Ther Corporate Directors

Intra-Cellular Ther corporate directors refer to members of an Intra-Cellular Ther board of directors. The board of directors generally takes responsibility for the Intra-Cellular Ther's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Intra-Cellular Ther's board members must vote for the resolution. The Intra-Cellular Ther board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.

Investing Intra-Cellular Ther

You need to understand the risk of investing before taking a position in Intra-Cellular Ther. The danger of trading Intra-Cellular Ther is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Intra-Cellular Ther is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Intra-Cellular Ther. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Intra-Cellular Ther is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Please see Risk vs Return Analysis. Note that the Intra-Cellular Ther information on this page should be used as a complementary analysis to other Intra-Cellular Ther's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Fundamental Analysis module to view fundamental data based on most recent published financial statements.

Complementary Tools for Intra-Cellular Stock analysis

When running Intra-Cellular Ther price analysis, check to measure Intra-Cellular Ther's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Intra-Cellular Ther is operating at the current time. Most of Intra-Cellular Ther's value examination focuses on studying past and present price action to predict the probability of Intra-Cellular Ther's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Intra-Cellular Ther's price. Additionally, you may evaluate how the addition of Intra-Cellular Ther to your portfolios can decrease your overall portfolio volatility.
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Global Correlations
Find global opportunities by holding instruments from different markets
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Is Intra-Cellular Ther's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Intra-Cellular Ther. If investors know Intra-Cellular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Intra-Cellular Ther listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
5.2 B
Quarterly Revenue Growth YOY
Return On Assets
Return On Equity
The market value of Intra-Cellular Ther is measured differently than its book value, which is the value of Intra-Cellular that is recorded on the company's balance sheet. Investors also form their own opinion of Intra-Cellular Ther's value that differs from its market value or its book value, called intrinsic value, which is Intra-Cellular Ther's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Intra-Cellular Ther's market value can be influenced by many factors that don't directly affect Intra-Cellular Ther's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Intra-Cellular Ther's value and its price as these two are different measures arrived at by different means. Investors typically determine Intra-Cellular Ther value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Intra-Cellular Ther's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.